“In extrapolating the results of After-80 to real-world clinical practice, we firstly have to remember that 70 percent to 80 percent of patients who were screened for this study were ultimately not enrolled,” he reiterated. “There would have been many reasons why so many patients were excluded, but it does emphasize that the study’s findings won’t apply to everyone over the age of 80 who presents with ACS.”

“As always, the decision making process needs to be individually tailored,” Dr. Psaltis said. “The patient’s pre-existing comorbid status, quality of life, cognitive function and personal wishes are all important factors that need to be taken into account.”

“Moreover, we should not just consider its potential benefits in terms of whether it will reduce mortality or risk of recurrent infarcts,” Dr. Psaltis added. “In certain individuals [older than] 90, an invasive approach may be taken to improve quality of life and symptom burden, help to keep patients in independent living at home, or reduce readmission rates to hospital or even the use of anti-anginal medications that can be associated with debilitating side-effects.”

Dr. Paul Erne from the University of Zurich in Switzerland, who heads the steering committee of the Acute Myocardial Infarction in Sweden (AMIS), stressed, “Conservative treatment does not result in a poor outcome in every patient and we need to know much more about differential approach.”

“However, active treatment remains a great option for part of the elderly patients,” regardless of age, he told Reuters Health by email. “Please note the increasing number of patients treated at age above 100 years which proves to be a good option if the patients want to live actively.”

Dr. Rahul Potluri, founder of the ACALM (Algorithm for Comorbidities, Associations, Length of Stay and Mortality) Study Unit, Birmingham, U.K., recently reviewed the role of angioplasty in octogenarian ACS patients.

He told Reuters Health by email, “This study is the most conclusive evidence to date, showing the benefits of an invasive approach in patients above the age of 80 with the most common types of ACS (namely NSTEMI and unstable angina). The findings are most surprising given that both the groups were very similar in terms of patient characteristics and medications taken, thus delineating the true benefit of the invasive strategy in the most controlled fashion and in a short follow-up period.”

The study did not have commercial funding and the researchers declared no competing interests.